Biogen prices MS pill at discount to Novartis rival
This article was originally published in Scrip
Executive Summary
Biogen Idec priced its new multiple sclerosis pill Tecfidera at about $54,900 a year, which is less than the average cost of Novartis’ rival drug Gilenya.